Helicobacter pylori and peptic ulcer

Area of Science:

• Gastroenterology
• Microbiology
• Pharmacology

Background:

• Helicobacter pylori (H. pylori) is a primary cause of gastric and duodenal ulcers.
• Ulcer healing and recurrence rates are strongly linked to H. pylori status.
• Current eradication regimens face challenges with efficacy, side effects, and compliance.

Purpose of the Study:

• To evaluate alternative regimens for H. pylori eradication.
• To assess the efficacy and tolerability of sucralfate in H. pylori treatment.
• To identify simpler, more effective, and safer H. pylori eradication strategies.

Main Methods:

• Review of clinical trials and studies on H. pylori eradication therapies.
• Comparison of triple therapy regimens including bismuth, antibiotics, and acid suppressors.
• Investigation of sucralfate's role as a potential substitute in triple therapy.

Main Results:

• Triple therapy with bismuth, metronidazole, and tetracycline/amoxicillin shows high eradication rates but significant side effects.
• Acid suppression combined with antibiotics is effective but costly with variable outcomes.
• Sucralfate substitution for bismuth in triple therapy demonstrated efficacy with improved tolerability.

Conclusions:

• Sucralfate offers a viable alternative to bismuth in triple therapy for H. pylori eradication.
• Developing an ideal H. pylori eradication regimen remains an ongoing challenge.
• Further research is needed to optimize treatment strategies for H. pylori infections.